8 June 2022 - - US-based biopharmaceutical company Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has appointed Saira Ramasastry to the company's board of directors and as a member of the audit committee, the company said.

Ramasastry is the managing partner of Life Sciences Advisory, LLC an independent firm that she founded to provide strategic advice and business development solutions for life science companies.

Prior to founding Life Sciences Advisory, Ramasastry spent 10 years as an investment banker with Merrill Lynch and company where she helped establish the biotechnology practice and advised on mergers and acquisitions, and strategic and capital market transactions.

Previously, she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella and Co., an investment banking firm.

Ramasastry currently serves on the board of directors for Day One Biopharmaceuticals, Inc. Vir biotechnology, Inc., Akouos, Inc., and Glenmark Pharmaceuticals, Ltd.

She is also a health innovator fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. Ramasastry holds an M.S. in management science and engineering and a B.A. in economics from Stanford University, as well as a M. Phil. in management studies from University of Cambridge.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of rare liver diseases.

Mirum's approved medication is Livmarli (maralixibat) oral solution which is approved in the United States for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.

Mirum's late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults.

Livmarli, an oral ileal bile acid transporter inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 clinical trial for progressive familial intrahepatic cholestasis and the EMBARK Phase 2b clinical trial for patients with biliary atresia.

In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for Livmarli for the treatment of cholestatic liver disease in patients with Alagille syndrome.

Mirum's second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.